TNOX Tanox (MM)

HOUSTON, Feb. 3 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will deliver company presentations this month at the BIO CEO & Investor Conference in New York City and the Deutsche Bank Small Cap Growth Conference in Naples, Fla. Tanox Medical Director, Dr. Stanley Lewis will provide an overview of the company's lead clinical antibody, TNX-355, as well as participate in a panel discussion during an HIV/AIDS focus session Feb. 14 at 4 p.m., EST, during BIO CEO. Tanox President and Chief Executive Officer Danong Chen will deliver a company update at the conference Feb. 15 at 12:30 p.m., EST. In addition, Tanox Vice President of Research Bing Yao, and Steve Sievert, director, Investor Relations & Corporate Communications will present at the Deutsche Bank conference Feb. 15 at 9 a.m., EST. Live webcasts of the presentations will be accessible from the Investor Relations section on the company's Web site at http://www.tanox.com/ . Presentation slides will be available on the site following the live address at each conference. About Tanox, Inc. Tanox is a biotechnology company specializing in the discovery and development of monoclonal antibodies. The company develops innovative biotherapeutics for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer. Tanox's lead investigational therapy, TNX-355, is a viral-entry inhibitor antibody to treat HIV/AIDS. TNX-355 has shown significant antiretroviral activity in Phase 2 clinical testing. Tanox's first-approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed allergic asthma. Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG and is approved for marketing in the United States, Canada and major European countries. Tanox is based in Houston and has a manufacturing facility in San Diego. Additional corporate information is available at http://www.tanox.com/ . http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGO DATASOURCE: Tanox, Inc. CONTACT: Steve Sievert of Tanox, Inc., +1-713-578-4211, or Web site: http://www.tanox.com/ http://ceo.bio.org/opencms/ceo/2006/index.jsp

Copyright